Literature DB >> 25486604

Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease.

Juha Grönholm1, Michael J Lenardo2.   

Abstract

Type 1 diabetes is a progressive autoimmune disease with no curative treatment, making prevention critical. At the time of diagnosis, a majority of the insulin secreting β-cells have already been destroyed. Insulitis, lymphocytic infiltration to the pancreatic islets, is believed to begin months to years before the clinical symptoms of insulin deficiency appear. Insulitis should be treated as its own disease, for it is a known precursor to autoimmune diabetes. Because it is difficult to detect insulitic cellular infiltrates noninvasively, considerable interest has been focused on the levels of islet autoantibodies in blood as measurable diagnostic markers for islet autoimmunity. The traditional islet autoantibody detection assays have many limitations. New electrochemiluminescence-based autoantibody detection assays have the potential to overcome these challenges and they offer promising, cost-effective screening tools in identifying high-risk individuals for trials of preventive interventions. Here, we outline diagnostic and therapeutic strategies to overcome pancreatic β-cell destroying insulitis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoantibody; Insulitis; Tolerance; Type 1 diabetes

Mesh:

Substances:

Year:  2014        PMID: 25486604      PMCID: PMC4336608          DOI: 10.1016/j.clim.2014.11.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  87 in total

Review 1.  Antigen-induced programmed T cell death as a new approach to immune therapy.

Authors:  J M Critchfield; M J Lenardo
Journal:  Clin Immunol Immunopathol       Date:  1995-04

2.  Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes.

Authors:  Sami Oikarinen; Sisko Tauriainen; Didier Hober; Bernadette Lucas; Andriani Vazeou; Amirbabak Sioofy-Khojine; Evangelos Bozas; Peter Muir; Hanna Honkanen; Jorma Ilonen; Mikael Knip; Päivi Keskinen; Marja-Terttu Saha; Heini Huhtala; Glyn Stanway; Christos Bartsocas; Johnny Ludvigsson; Keith Taylor; Heikki Hyöty
Journal:  Diabetes       Date:  2013-09-05       Impact factor: 9.461

3.  Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

Authors:  Jennifer M Barker; Katherine J Barriga; Liping Yu; Dongmei Miao; Henry A Erlich; Jill M Norris; George S Eisenbarth; Marian Rewers
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

4.  Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes.

Authors:  Peter Achenbach; Kerstin Koczwara; Annette Knopff; Heike Naserke; Anette-G Ziegler; Ezio Bonifacio
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.

Authors:  Leonard C Harrison; Margo C Honeyman; Cheryl E Steele; Natalie L Stone; Elena Sarugeri; Ezio Bonifacio; Jennifer J Couper; Peter G Colman
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

6.  Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine.

Authors:  L C Harrison; P G Colman; B Dean; R Baxter; F I Martin
Journal:  Diabetes       Date:  1985-12       Impact factor: 9.461

7.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

Authors:  C R Stiller; J Dupré; M Gent; M R Jenner; P A Keown; A Laupacis; R Martell; N W Rodger; B von Graffenried; B M Wolfe
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

8.  Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.

Authors:  G S Eisenbarth; S Srikanta; R Jackson; S Rabinowe; R Dolinar; T Aoki; M A Morris
Journal:  Diabetes Res       Date:  1985-11

9.  Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice.

Authors:  J S Petersen; A E Karlsen; H Markholst; A Worsaae; T Dyrberg; B Michelsen
Journal:  Diabetes       Date:  1994-12       Impact factor: 9.461

10.  Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen.

Authors:  K P Böhmer; H Kolb; B Kuglin; J Zielasek; A Hübinger; E F Lampeter; B Weber; V Kolb-Bachofen; H U Jastram; J Bertrams
Journal:  Diabetes Care       Date:  1994-02       Impact factor: 19.112

View more
  1 in total

1.  Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice.

Authors:  Juha Grönholm; Philippe P Pagni; Minh N Pham; Claire B Gibson; Paul F Macomber; José Luis Vela; Matthias von Herrath; Michael J Lenardo
Journal:  Diabetologia       Date:  2017-04-28       Impact factor: 10.122

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.